Idenix defends nucleoside analogue patent in EPO opposition against five opponents
Client(s) Idenix Pharmaceuticals LLC
Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs. The subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV. The patent covers Gilead's marketing of Sovaldi® and Harvoni® for the treatment of Hepatitis C.
Opposition Proceedings EP 1 523 489